Sector News

Alexion Pharma Appoints Leonard Bell As Chairman

October 13, 2014
Life sciences
(RTTNews) – Alexion Pharmaceuticals Inc. announced that it has appointed Leonard Bell as Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company.
 
In addition, Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Norby, who was voted Lead Independent Director by the other independent members of the Board, has been a Director of Alexion since September 1999. Norby currently serves as Chair of the Audit Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Risk and Strategy Committee.
 
Both of these appointments follow the passing of Max Link, Ph.D., as announced earlier this week, who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the Company’s inception in 1992.

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach